Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 3/20 | 0.31 |
| ▸ | SGK1 | O00141 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962285 | 0.87 | CXCR2 (0.40) | CXCR2PLK1SGK1PLK4CHEK1 | |
| SCHEMBL16683780 | 0.77 | CXCR2 (0.36) | CXCR2PLK1SGK1PLK4CHEK1 | |
| SCHEMBL18772376 | 0.75 | CXCR2 (0.33) | CXCR2 | |
| SCHEMBL8229788 | 0.72 | CXCR2 (0.33) | CXCR2POLBGAA | |
| SCHEMBL17899042 | 0.71 | PLK1 (0.37) | CXCR2PLK1SGK1PLK4CHEK1 | |
| SCHEMBL14586289 | 0.71 | CXCR2 (0.30) | CXCR2 | |
| SCHEMBL22854003 | 0.70 | HDAC1 (0.32) | CXCR2 | |
| SCHEMBL14327880 | 0.70 | CXCR2 (0.41) | CXCR2POLBGAA | |
| SCHEMBL11934537 | 0.70 | CXCR2 (0.32) | CXCR2POLBGAA | |
| SCHEMBL7598100 | 0.67 | GAA (0.49) | POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190209696-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912836-B2 | Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | CXCR2 2570/4885PLK1 365/4885SGK1 2114/4885 |
| US-20190209696-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | CXCR2 2570/4885PLK1 365/4885SGK1 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.